{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:15:18Z","timestamp":1791825318933,"version":"4.3.4"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Successful use of carbapenems in combination with cefazolin or oxacillin for treatment of MSSA bacteraemia has been described; however, comparative data to standard treatment approaches are lacking.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a multicentre, retrospective study of adult patients with MSSA bacteraemia for &amp;gt;48 h. Standard treatment was considered monotherapy with cefazolin, oxacillin or nafcillin. Combination therapy was defined as the addition of ertapenem or meropenem to standard treatment for at least 24 h. The primary outcome was duration of bacteraemia defined as time from administration of an antibiotic with in vitro activity to first negative blood culture. Time to blood culture sterilization was compared through risk-set matching with aid of a propensity score.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 238 patients were included; 66% (157\/238) received standard treatment and 34% (81\/238) received combination therapy. The median (IQR) time to carbapenem initiation was 4.7 (3.63\u20136.5) days. Patients who received combination therapy were younger (P\u200a=\u200a0.012), more likely to have endocarditis (P\u200a=\u200a0.034) and had longer median duration of bacteraemia (P\u200a&amp;lt;\u200a0.001). After applying risk-set matching, patients who received combination therapy experienced faster time to blood culture sterilization compared with control patients [HR\u200a=\u200a1.618 (95% CI; 1.119\u20132.339) P\u200a=\u200a0.011]. Using a paired hazard model, 90 day mortality rates were not statistically different among patients who received combination therapy versus matched controls [HR\u200a=\u200a1.267 (95% CI; 0.610\u20132.678), P\u200a=\u200a0.608].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>Carbapenem combination therapy resulted in faster time to blood culture sterilization, but no differences in overall mortality rates. Randomized trials are critical to determine the utility of carbapenem combination therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae198","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T07:17:30Z","timestamp":1719818250000},"page":"1990-1997","source":"Crossref","is-referenced-by-count":12,"title":["Carbapenem combination therapy versus standard of care for persistent methicillin-susceptible <i>Staphylococcus aureus<\/i> bacteraemia"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-1451","authenticated-orcid":false,"given":"Sunish","family":"Shah","sequence":"first","affiliation":[{"name":"Antibiotic Management Program, University of Pittsburgh Medical Center , Pittsburgh, PA , USA"},{"name":"Department of Pharmacy, University of Pittsburgh Medical Center , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd G","family":"Clarke","sequence":"additional","affiliation":[{"name":"Antibiotic Management Program, University of Pittsburgh Medical Center , Pittsburgh, PA , USA"},{"name":"Department of Pharmacy, University of Pittsburgh Medical Center , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Ludwig","sequence":"additional","affiliation":[{"name":"Office of Quality and Clinical Research Innovation, University of Pittsburgh Medical Center , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Burgdorf","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo D","family":"Arbulu Guerra","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9794-5665","authenticated-orcid":false,"given":"Ryan K","family":"Shields","sequence":"additional","affiliation":[{"name":"Antibiotic Management Program, University of Pittsburgh Medical Center , Pittsburgh, PA , USA"},{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"key":"2024073123520802800_dkae198-B1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2024073123520802800_dkae198-B2","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1469-0691.2010.03425.x","article-title":"Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia?","volume":"17","author":"Paul","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2024073123520802800_dkae198-B3","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1177\/10600280231158809","article-title":"Therapeutic options for adult patients with persistent methicillin-susceptible Staphylococcus aureus bacteremia: a narrative review","volume":"57","author":"Chastain","year":"2023","journal-title":"Ann Pharmacother"},{"key":"2024073123520802800_dkae198-B4","doi-asserted-by":"crossref","first-page":"dlab148","DOI":"10.1093\/jacamr\/dlab148","article-title":"Oxacillin plus ertapenem combination therapy leads to rapid blood culture clearance and positive outcomes among patients with persistent MSSA bacteraemia: a case series","volume":"3","author":"El-Dalati","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2024073123520802800_dkae198-B5","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/cid\/ciz995","article-title":"Cefazolin and ertapenem salvage therapy rapidly clears persistent methicillin-susceptible Staphylococcus aureus bacteremia","volume":"71","author":"Ulloa","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024073123520802800_dkae198-B6","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1128\/AAC.01192-16","article-title":"Cefazolin and ertapenem, a synergistic combination used to clear persistent Staphylococcus aureus bacteremia","volume":"60","author":"Sakoulas","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123520802800_dkae198-B7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/phar.2745","article-title":"Treatment of persistent methicillin-susceptible Staphylococcus aureus bacteremia and presumed osteomyelitis with oxacillin and ertapenem in a premature neonate","volume":"43","author":"Hitchins","year":"2023","journal-title":"Pharmacotherapy"},{"key":"2024073123520802800_dkae198-B8","doi-asserted-by":"crossref","first-page":"ofac159","DOI":"10.1093\/ofid\/ofac159","article-title":"Potent activity of ertapenem plus cefazolin within staphylococcal biofilms: a contributing factor in the treatment of methicillin-susceptible Staphylococcus aureus endocarditis","volume":"9","author":"Gilbertie","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2024073123520802800_dkae198-B9","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1111\/jocs.16491","article-title":"Oxacillin plus ertapenem rapidly clears persistent left ventricular assist device-related methicillin-susceptible Staphylococcus aureus bacteremia","volume":"37","author":"Wilsey","year":"2022","journal-title":"J Card Surg"},{"key":"2024073123520802800_dkae198-B10","first-page":"6828538","article-title":"Persistent methicillin-susceptible bacteremia rapidly cleared with cefazolin and ertapenem combination therapy in a patient with COVID-19","volume":"2022","author":"Ilges","year":"2022","journal-title":"Case Rep Infect Dis"},{"key":"2024073123520802800_dkae198-B11","first-page":"547","article-title":"Clearance of persistent Staphylococcus aureus bacteremia in a preterm neonate with the use of combination cefazolin and ertapenem","volume":"25","author":"Akers","year":"2020","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2024073123520802800_dkae198-B12","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"2024073123520802800_dkae198-B13","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1198\/016214501753208573","article-title":"Balanced risk set matching","volume":"96","author":"Li","year":"2001","journal-title":"J Am Stat Assoc"},{"key":"2024073123520802800_dkae198-B14","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1541-0420.2005.00356.x","article-title":"Propensity score matching with time-dependent covariates","volume":"61","author":"Lu","year":"2005","journal-title":"Biometrics"},{"key":"2024073123520802800_dkae198-B15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"2024073123520802800_dkae198-B16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/00031305.1985.10479383","article-title":"Constructing a control group using multivariate matched sampling methods that incorporate the propensity score","volume":"39","author":"Rosenbaum","year":"1985","journal-title":"Am Stat"},{"key":"2024073123520802800_dkae198-B17","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1214\/08-AOAS187","article-title":"For objective causal inference, design trumps analysis","volume":"2","author":"Rubin","year":"2008","journal-title":"Ann Appl Stat"},{"key":"2024073123520802800_dkae198-B18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/biomet\/61.1.17","article-title":"Survival analyses in twin studies and matched pair experiments","volume":"61","author":"Holt","year":"1974","journal-title":"Biometrika"},{"key":"2024073123520802800_dkae198-B19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1198\/106186006X137047","article-title":"Optimal full matching and related designs via network flows","volume":"15","author":"Hansen","year":"2012","journal-title":"J Comput Graph Stat"},{"key":"2024073123520802800_dkae198-B20","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1001\/archinte.163.17.2066","article-title":"Clinical identifiers of complicated Staphylococcus aureus bacteremia","volume":"163","author":"Fowler","year":"2003","journal-title":"Arch Intern Med"},{"key":"2024073123520802800_dkae198-B21","doi-asserted-by":"crossref","first-page":"ofac653","DOI":"10.1093\/ofid\/ofac653","article-title":"All-cause and infection-related mortality in Staphylococcus aureus bacteremia, a multicenter prospective cohort study","volume":"9","author":"van der Vaart","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2024073123520802800_dkae198-B22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cmi.2020.10.016","article-title":"Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review","volume":"27","author":"Palacios-Baena","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2024073123520802800_dkae198-B23","doi-asserted-by":"crossref","first-page":"ofab327","DOI":"10.1093\/ofid\/ofab327","article-title":"Clinical outcomes with definitive treatment of methicillin-resistant Staphylococcus aureus bacteremia with retained daptomycin and ceftaroline combination therapy vs de-escalation to monotherapy with vancomycin, daptomycin, or ceftaroline","volume":"8","author":"Nichols","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2024073123520802800_dkae198-B24","doi-asserted-by":"crossref","first-page":"ofz538","DOI":"10.1093\/ofid\/ofz538","article-title":"Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments","volume":"7","author":"McCreary","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2024073123520802800_dkae198-B25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2796.2005.01598.x","article-title":"Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients","volume":"259","author":"Ruotsalainen","year":"2006","journal-title":"J Intern Med"},{"key":"2024073123520802800_dkae198-B26","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1093\/cid\/ciaa1000","article-title":"Adjunctive daptomycin in the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a randomized, controlled trial","volume":"72","author":"Cheng","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024073123520802800_dkae198-B27","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0140-6736(17)32456-X","article-title":"Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Thwaites","year":"2018","journal-title":"Lancet"},{"key":"2024073123520802800_dkae198-B28","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/cid\/ciad558","article-title":"Considerations and concerns regarding the use of ertapenem in patients with hypoalbuminemia: is it truly inappropriate?","volume":"78","author":"Phinder-Puente","year":"2024","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/8\/1990\/58689013\/dkae198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/8\/1990\/58689013\/dkae198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T06:05:40Z","timestamp":1722492340000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/8\/1990\/7701981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,7,1]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae198","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,7,1]]}}}